banter and General Discussion, page-9103

There was a lot of discussion in Oz about it. CSL had a two day fall from $A305 to $A282.25 yesterday BEFORE the big fall in US markets, purely based on the CSL failed heart trial. That's a market cap loss of $A11bn or $US7.1bn. It's a reminder of how much a successful trial could add to the Meso market cap. Adding $US7.1bn to the market cap would take Meso up to $US71.90 per MESO ADR ($A11.10 per MSB Aussie share).Note these are not my valuations, just an indication of what a similar mkt cap move would do to the Meso share price IF it happened. It would probably require a confirmatory trial by Meso showing similar spectacular reductions in MACE - cardiac death, strokes and heart attacks as Dr Perin achieved for Meso in the DREAM trial. An accelerated approval in paediatric HLHS or LVAD would also get a big vote of confidence from the market.The market is clearly not pricing any of this into the Meso price at present - in large part because of poor communications by Meso and a loss of confidence in SI by instos. As several people have said, it would be very cheap for CSL to buy Meso and get access to the whole portfolio for a fraction of the value of the CSL heart market cap.
E
Aloha.